Target blood pressure in patients with diabetes: Asian perspective

Yonsei Medical Journal

Volumn 57, Issue 6, 2016, Pages 1307-1311

  Park, Sungha ^a   Kario, Kazuomi ^b   Park, Chang Gyu ^c   Huang, Qi Fang ^d   Cheng, Hao Min ^e   Hoshide, Satoshi ^b   Wang, Ji Guang ^d   Chen, Chen Huan ^e  

^a Yonsei University College of Medicine   (South Korea)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c Korea University College of Medicine   (South Korea)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Blood pressure; Coronary artery disease; Diabetes; Hypertension; Stroke J curve

Indexed keywords

RAMIPRIL; TELMISARTAN; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ASIA; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; AGED; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; HYPOTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; RISK FACTOR; STROKE;

AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; HYPOTENSION; MALE; MIDDLE AGED; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES; RISK FACTORS; STROKE;

EID: 84986913705     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2016.57.6.1307     Document Type: Review

References (23)

1. Ravid M, Savin H, Lang R, Jutrin I, Shoshana L, Lishner M. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. A 14-year follow-up report on 195 patients. Arch Intern Med 1992;152:1225-9.
2. Pell S, D’Alonzo CA. Some aspects of hypertension in diabetes mellitus. JAMA 1967;202:104-10.
3. Lipman ML, Schiffrin EL. What is the ideal blood pressure goal for patients with diabetes mellitus and nephropathy? Curr Cardiol Rep 2012;14:651-9.
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-44.
5. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 2012;59:74-83.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72.
7. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536.
8. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31: 1281-357.
9. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmel-farb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20.
10. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care 2016;39(Suppl 1):S60-71.
11. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
12. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.
13. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
14. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-8.
15. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003;21:707-16.
16. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011;123:2799-810.
17. Kawamori R, Fujita T, Matsuoka H, Umemura S, Saito Y. Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: challenge-DM study. Diabetes Res Clin Pract 2009;83:241-8.
18. Ogihara T, Saruta T, Rakugi H, Fujimoto A, Ueshima K, Yasuno S, et al. Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial. Hypertens Res 2009;32:248-54.
19. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005;16:3027-37.
20. Chiang CE, Wang TD, Ueng KC, Lin TH, Yeh HI, Chen CY, et al. 2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. J Chin Med Assoc 2015;78:1-47.
21. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014;37: 253-390.
22. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
23. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016;352:i717.